Insuman Comb 50

Insulin human, the active ingredient in Insuman Comb 50, is an insulin presented as a subcutaneous injectable formulation for subcutaneous use. It treats hyperglycemia in both type 1 and type 2 diabetes mellitus, providing basal and prandial glucose control and is approved for use in the European Union market.

GNH USA supplies Insuman Comb 50 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, with rigorous quality assurance and cold‑chain logistics.

Insuman Comb 50 is an insulin that acts on glucose metabolism to manage diabetes mellitus.

- Type 1 diabetes mellitus: provides essential insulin replacement to control blood glucose. - Type 2 diabetes mellitus: improves glycemic control when oral agents are insufficient. - Insulin deficiency states: supplies basal and prandial insulin to maintain glucose homeostasis. - Gestational diabetes mellitus: may be used under specialist supervision to achieve target glucose levels.

The most frequently reported adverse reactions to Insuman Comb 50 involve glucose levels and injection sites.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosage is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: gradual increase in body weight associated with improved glycemic control. - Lipodystrophy: localized fat accumulation or loss at repeated injection sites.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Allergic reactions: rash, urticaria, or angioedema indicating hypersensitivity. - Anaphylaxis: rare life‑threatening systemic allergic response. - Insulin antibody formation: may alter insulin action and cause unpredictable glucose levels.

When using Insuman Comb 50, clinicians and patients should observe several safety measures.

- Dose adjustment: titrate based on self‑monitoring of blood glucose and clinical response. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose promptly. - Concomitant medications: review drugs that may mask hypoglycemia or potentiate insulin effects. - Pregnancy and lactation: use only if benefits outweigh potential risks; consult healthcare provider. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 50 may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Beta‑blockers: may mask symptoms of hypoglycemia, complicating detection. - MAO‑inhibitors: can potentiate insulin’s glucose‑lowering effect, increasing hypoglycemia risk.

Moderate Interactions (Monitor Closely): - Oral hypoglycemics (e.g., sulfonylureas, meglitinides): additive glucose‑lowering effect; monitor blood glucose. - Corticosteroids: may raise blood glucose, requiring insulin dose adjustments. - Thiazide diuretics: can impair glucose tolerance, necessitating closer monitoring.